Navigation Links
Accuray Announces Four New Products at Nation's Leading Radiation Oncology Meeting
Date:10/29/2007

beams from each treatment position (as opposed to delivering with one collimator size from many positions, then switching to a new size to deliver from many positions, then switching to the next size and so on). This makes multiple collimator sized treatments much faster, allowing clinicians to safely deliver such a treatment in as little as half the time. The Iris Collimator enables clinicians to create and deliver practical multi-collimator treatments that have greater accuracy, more uniformity and better avoidance of nearby critical structures and healthy tissue than single collimator treatments.

800 MU/min LINAC

Currently the CyberKnife System features a compact linear accelerator capable of delivering 600 monitor units per minute. A monitor unit (MU) is the measure of machine output for a linear accelerator (LINAC) in radiation therapy and radiation dose rate typically is measured in MU/minute.

Accuray is announcing the introduction of an 800 MU/min LINAC, which is capable of delivering higher dose rates of radiation to a tumor, thereby reducing treatment times. This advanced new 800 MU/min linear accelerator system will not only be incorporated into the current CyberKnife offering, it will also serve as the platform for future technologies.

Sequential Optimization Planning Tool

The Sequential Optimization feature is an optimization capability that will now be available as a software option for the MultiPlan(R) Treatment Planning System. The technology allows users to optimize their treatment objectives based on each unique clinical situation using prioritized clinical objectives, instead of the traditional trial and error setting of various constraints to narrow in on an optimized treatment. This enables users to establish their own clinical objectives to achieve high quality, more intuitive treatment planning in a shorter amount of time.

RoboCouch(R) Patient Positioning System with Seated Load The RoboCouch(R) Patient Posi
'/>"/>

SOURCE Accuray Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 (HealthDay --, Treatment for lymphoma may lower ... and non-Hodgkin lymphoma, which are cancers of the body,s ... still in their reproductive years. For men, treatment for ... most men regain their fertility within two years of ... about the possibility of this significant side effect before ...
(Date:7/25/2014)... The American Society of Anesthesiologists (ASA) today announced ... (PSH) Learning Collaborative, a national initiative designed to ... surgery. More than 40 leading health care ... the collaborative, which will convene for the first ... July 25-26, in Schaumburg, Ill. , The PSH ...
(Date:7/25/2014)... The new report “Carbohydrase Market ... and Others), by Type (Amylases, Cellulases, and Others), ... Global Trends & Forecasts to 2019", by MarketsandMarkets, ... global Carbohydrase market with analysis of trends, opportunities, ... and values are forecasted on the basis of ...
(Date:7/25/2014)... Richardson, Texas (PRWEB) July 25, 2014 ... years of operations at their office location by expanding ... first of a kind comprehensive visual electro-physiology clinic. , ... and with years of experience in vision problems, patients ... studies can now take advantage of the implementation of ...
(Date:7/25/2014)... European liquid chromatography reagents report defines and segments the ... revenue. The liquid chromatography reagents market in Europe was ... estimated to grow to around $1581.8 million by 2018, ... 2018. , Browse through the TOC of the European ... the in-depth analysis provided. This also provides a glimpse ...
Breaking Medicine News(10 mins):Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4
... According to a study of patients, doctors and family ... When someone has a terminal illness, they may have ... 'living will'. For example they may not wish to ... realistic chance of recovery. But other people, even though ...
... better than conventional treatment for managing asthma attacks. ... immune cells known eosinophils increase// in the airways. ... how targeting this build up of eosinophils in ... asthma attack. ,The conventional treatment consists ...
... is observed that statins reduce the risk of heart attack ... and so lowers the risk of heart disease. This has ... the benefits for the elderly have not been so clear. ... the benefit of treatment with the statin drug pravastatin in ...
... new study observed that people reporting symptoms of anxiety were ... It was long believed that worry gave you ulcers.// ... pylori was a major risk factor, and the link with ... now report that people with generalized anxiety do seem to ...
... with animals say they have located the genes related ... they say it could one day lead to better ... research into this area was only able to locate ... of how the genes work together during memory formation. ...
... researchers observe that stress hormones may be disregulated in ... a hormonal system that helps the body deal with ... production of the stress hormone cortisol by the adrenal ... pains and overwhelming tiredness. It's cause is not well ...
Cached Medicine News:
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... a corporate update and report second quarter 2014 financial ... Friday, August 1, 2014. That same day, Arena will ... Eastern Time (5:30 a.m. Pacific Time). ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/24/2014)... 2014  Parnell Pharmaceuticals Holdings Ltd announces the ... added to Parnell,s already extensive pipeline through a ... biotechnology company. The compounds now known as PAR ... bone regeneration and dermal regeneration, respectively. Parnell has ... the veterinary market with the potential to also ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... VIENNA, Va., Nov. 3 CEL-SCI Corporation,(NYSE: ... expanded its exclusive licensing,agreement for Multikine(R) with Orient ... from Taiwan. The new,agreement extends the Multikine collaboration ... New Zealand. The licensing agreement,initially focuses on the ...
... - Data presented at the 2008 iSBTc Annual Meeting ... at 11:00 a.m. ET to discuss,results -, BRANFORD, ... announced today preliminary data from an ongoing Phase II,trial ... treatment of patients with unresectable Stage III or Stage ...
Cached Medicine Technology:CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7
... Portable - Battery Powered (6 size AA ... conversion (g, ct, oz, ozt, GN, dwt, ... Counting and Percent Measure functions, Auto Print. ... Optional AC adapter may be ordered for ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... calibration with external weights only (selectable ...
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Medicine Products: